Investigation of the effect of Womentex Barij capsule on polycystic ovary syndrome

Investigation of the effectiveness of Womentex Barij capsule on hormonal and clinical symptoms of polycystic ovary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130211012438N28

Enrollment

Registered

2018-11-07

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Womentex capsule 300 mg, Produced in Barij Essence Pharmaceutical Company, 3 times per day for 3 months orally. Intervention 2: Control group:placebo capsule 300mg,

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Higher than 5 years of their disease Aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Hypothyroidism Hyperprolactinemia Congenital adrenal hyperplasia Ovarian and adrenal neoplasms Taking corticosteroids Infertility Diabetes

Design outcomes

Primary

Measure	Time frame
Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Fasting Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Glucose oxidase Method.;Glucose tolerance test. Timepoint: Baseline and End-of-trial. Method of measurement: Glucose oxidase Method.;Luteinizing hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Follicular- stimulating hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Dehydroepiandrosterone sulfate. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;17-Hydroxyprogesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.	—

Measure

Time frame

Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Fasting Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Glucose oxidase Method.;Glucose tolerance test. Timepoint: Baseline and End-of-trial. Method of measurement: Glucose oxidase Method.;Luteinizing hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Follicular- stimulating hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Dehydroepiandrosterone sulfate. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;17-Hydroxyprogesterone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.;Testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Using ELISA Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Taghizadeh

Kashan University of Medical Sciences

taghizadeh_m@kaums.ac.ir+98 36 1555 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026